evipedia.ai
← Back

Red Yeast Rice for Health & Longevity

Created on 11/06/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Red yeast rice, rice fermented with a mold and sold as a supplement to lower cholesterol, contains the same molecule as a prescription cholesterol-lowering drug. It lowers the cholesterol that builds up in artery walls when products contain enough of it, but strength varies widely between brands. Prevention of heart attacks rests on a single trial in heart-attack survivors. Risks include rare muscle and liver injury and contaminated products. (Full Review)

Protocol

Standardized extract regimen (CCSPS)
1,200 mg/day
Xuezhikang 600 mg twice daily for about 4.5 years in heart-attack survivors
Monacolin-based dosing
3–10 mg monacolin K daily
EU products must stay below 3 mg
Time of day
Typically with the evening meal
Food raises lovastatin absorption by about half
Time to effect
LDL cholesterol lowering
6–8 weeks
Falls by up to 15–25%, per a review; trials typically measured at 8–12 weeks
Fewer coronary events and deaths after a heart attack
Years
Any event reduction depends on years of sustained lowering; CCSPS treated for about 4.5 years

Benefits

Contraindications
  • Pregnancy, possible pregnancy and breastfeeding
  • People under 18 or over 70 years
  • Active liver disease or unexplained persistent transaminase elevation
  • Strong CYP3A4 inhibitors (itraconazole, ketoconazole, clarithromycin)
  • Prescription statins (atorvastatin, rosuvastatin) and other cholesterol-lowering drugs (e.g., ezetimibe)
  • Gemfibrozil and cyclosporine
  • Severe kidney impairment (creatinine clearance 10–30 mL/min)
  • SLCO1B1 poor-function genotype
  • Prior statin-associated rhabdomyolysis or immune-mediated necrotizing myopathy
    •
Key Interactions
  • Other fibrates (such as fenofibrate) and niacin supplements of 1 g/day or more: additive myopathy risk
  • Diltiazem, verapamil, dronedarone, amiodarone and danazol: raise lovastatin exposure and myopathy risk; lovastatin capped at 20 mg daily (40 mg with amiodarone)
  • Colchicine and ranolazine: myopathy, including rhabdomyolysis, reported with colchicine; ranolazine may increase that risk
  • Warfarin and other coumarin anticoagulants: bleeding and prolonged prothrombin time reported
  • Grapefruit juice: raises lovastatin exposure and myopathy risk
  • Cimetidine and spironolactone: possible additive blunting of steroid production
  • Alcohol in substantial quantities: higher liver-injury risk
    •
Theoretical (inferred from mechanism)
  • Berberine: additive LDL lowering and raised monacolin K exposure
  • Plant sterols, psyllium and policosanol: additive LDL lowering
  • Coenzyme Q10: lower coenzyme Q10 production
  • St John's wort, carbamazepine and rifampin: lower monacolin K levels and reduced LDL lowering
  • Goldenseal and other herbal CYP3A4 inhibitors: raised monacolin K levels and muscle risk
  • Drugs cleared by CYP2C9, CYP1A2 or P-glycoprotein, such as warfarin and verapamil: altered drug levels
    •

Risk & Side Effects

  • High:
  • Medium:
  • Low: Muscle pain, myopathy and rhabdomyolysis; liver injury; kidney injury from contaminated products; new-onset diabetes; gastrointestinal and other mild adverse events; allergic reactions and anaphylaxis; fetal harm; immune-mediated necrotizing myopathy; cognitive impairment
    •
  • Speculative: Unstudied companion monacolins
    •

Monitoring

Marker Target Why
LDL cholesterol 50–99 mg/dL Confirms product potency
ApoB About 50–130 mg/dL Expected to fall with LDL
ALT About 7–56 U/L Liver safety check
AST Not specified in the ER Second liver enzyme, paired with ALT
CK About 30–200 U/L Muscle safety check when symptoms appear
Creatinine and eGFR Creatinine about 0.6–1.3 mg/dL; eGFR 60 mL/min/1.73 m² or above Contamination-related kidney injury and rhabdomyolysis
Urine glucose and protein Not specified in the ER Kidney safety check
HbA1c 4.0–5.6% Statin-type glucose rise
Fasting glucose Not specified in the ER Paired with HbA1c

Cadence: Baseline before starting; 6–8 weeks after starting or changing product, then every 6–12 months; CK whenever unexplained muscle pain or weakness appears

Qualitative Assessment

  • Muscle aches, cramps or weakness, especially in thighs and shoulders
  • Dark urine, reduced urine output or swelling
  • Fatigue, loss of appetite, upper-right abdominal discomfort or yellowing of skin or eyes
  • Digestive upset after starting a new product
  • Exercise tolerance and recovery compared with before starting
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.